🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Loxo Oncology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our UK, USA, China, Ireland and India registers with Loxo Oncology as lead sponsor. Synced 26 Sep 2026
7Current trials
2Recruiting now
14Drugs in these trials
5Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Loxo Oncology is the lead sponsor of 7 current clinical trials in our UK, USA, China, Ireland and India registers. 2 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Pirtobrutinib, Rituximab and Bendamustine. The most-studied condition is Chronic Lymphocytic Leukemia.

ClinicalTrials.gov trials by status

  • Recruiting229%
  • Active, closed571%

Trials by phase

  • Phase 3686%
  • Phase 2114%
01

Clinical trials sponsored by Loxo Oncology

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell
Phase 3 Recruiting 2022-07 UK, USA, China
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2 Recruiting 2025-01 UK, USA
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337 · Medullary Thyroid Cancer
Phase 3 Active, closed 2020-02 UK, USA, India, China
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3 Active, closed 2021-09 Ireland, UK, USA, China
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3 Active, closed 2021-03 Ireland, UK, USA, China
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3 Active, closed 2021-09 UK, USA, China
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255 · ClinicalTrials.gov ↗ · Lymphoma, Mantle-Cell
Phase 3 Active, closed 2021-04 UK, USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Loxo Oncology trials

14 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Loxo Oncology trials

6 conditions
Chronic Lymphocytic Leukemia5Small Lymphocytic Lymphoma5Medullary Thyroid Cancer1Leukemia, Lymphocytic1Leukemia, B-cell1Lymphoma, Mantle-Cell1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in UK72
Clinical trials in USA72
Clinical trials in China61
Clinical trials in Ireland20
Clinical trials in India10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Chronic Lymphocytic Leukemia

SponsorTrials
Acerta Pharma8
BeOne Medicines7
Ascentage Pharma Group3
Kartos Therapeutics1
Cellectar Biosciences1
Sana Biotechnology1

Sponsors with the most current trials registered for this condition.

06

Questions about Loxo Oncology trials

How many clinical trials does Loxo Oncology sponsor?

Loxo Oncology is the lead sponsor of 7 current trials on ClinicalTrials.gov in our UK, USA, China, Ireland and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Loxo Oncology trials recruiting?

Yes. 2 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Loxo Oncology testing?

Its current trials name 14 drugs and biologicals as interventions. The most frequent are Pirtobrutinib (6), Rituximab (3), Bendamustine (2), Ibrutinib (2) and Truxima (2). The number in brackets is how many of its trials name each drug.

Does Loxo Oncology have clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.